Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P040013/S033

GEM21S Growth Factor Enhanced Matrix Implementation of Restricted Access Barrier System (RABS) at Pyramid

Lynch Biologics, LLC · Decision date Aug 3, 2026

FDA DECISIONP040013/S033

What did the FDA approve?

FDA records P040013/S033 as a supplement to PMA P040013, with the supplement type “135 Review Track For 30-Day Notice”. The recorded decision is approval, dated Aug 3, 2026.

FDA approval order statement

implementation of a Restricted Access Barrier System (RABS) to the syringe filler unit for the filling of the rhPDGF-BB syringe component of GEM21S
Regulatory pathway
PMA supplement
Supplement type
135 Review Track For 30-Day Notice
Clinical specialty
Dental
Decision date
Aug 3, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P040013/S033
Regulatory pathway
PMA supplement
Product code
NPZ
Decision code
APPR
Decision date
Aug 3, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Bone grafting material, dental, with biologic component.

Product code
NPZ
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P040013/S033 received

    Application receipt date recorded by FDA.

  2. P040013/S033 · FDA decision

    135 Review Track For 30-Day Notice

Timeline entries are records held by MedtechLedger for P040013. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code NPZ

Product / regulatory recordCompanyPathwayDecision dateSource
INFUSE BONE GRAFTP050053/S066
Medtronic, Inc.PMA supplementAug 26, 2026FDA
Infuse Bone GraftP050053/S069
Medtronic, Inc.PMA supplementJul 28, 2026FDA
INFUSE Bone GraftP050053/S068
Medtronic, Inc.PMA supplementMar 19, 2026FDA
INFUSE Bone GraftP050053/S067
Medtronic, Inc.PMA supplementFeb 24, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Lynch Biologics, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
5526 Joseph St., Franklin, TN, 37064

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records